…
Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. It operates in two segments, Aflac Japan and Aflac U.S. The Aflac Japan segment offers cancer, medical, nursing care, whole life, and GIFT insurance products, as well as WAYS and child endowment, and Tsumitasu insurance products in Japan. Its Aflac U.S. segment provides accident, disability, cancer, critical illness, hospital indemnity, dental, vision, and life insurance products in the United States. The company also provides hearing, final expense, pet, Medicare supplement, supplemental dental and vision, short-term disability, and absence management insurance products, as well as cafeteria plans. It sells its products to individuals, families, and business owners through individual, independent corporate, and affiliated corporate agencies; banks; independent associates/career agents; and brokers. Aflac Incorporated was founded in 1955 and is headquartered in Columbus, Georgia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Aflac Incorporated is a US insurer selling supplemental health and life insurance primarily in Japan and the United States. Long-term growth may be supported by aging populations driving steady demand for supplemental coverage, scale in core markets, and an investment portfolio; investors may find it attractive for its market position and ability to support returns.
Principal risks include significant currency and geographic concentration from its Japan business, sensitivity of earnings to investment yields and market volatility, and underwriting, regulatory and competitive pressures that could affect margins and reserving.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 4533.00M | 6417.00M | 5262.00M | 4869.00M | 5322.00M |
| Net income | 3646.00M | 5443.00M | 4659.00M | 4418.00M | 4325.00M |
| Selling general administrative | 2451.00M | 2790.00M | 2928.00M | 256.00M | 287.00M |
| Selling and marketing expenses | 246.00M | 181.00M | 188.00M | - | - |
| Gross profit | 6788.00M | 6815.00M | 18841.00M | 18865.00M | 22106.00M |
| Ebit | 4651.00M | 6417.00M | 5457.00M | 5095.00M | 5322.00M |
| Ebitda | 5525.00M | 6417.00M | 5262.00M | 4830.00M | 5322.00M |
| Depreciation and amortization | 874.00M | - | 39.00M | -265.00M | 1170.00M |
| Operating income | 4641.00M | 6417.00M | 5262.00M | 5095.00M | 5322.00M |
| Other operating expenses | 12797.00M | 12711.00M | 13579.00M | 14271.00M | 16784.00M |
| Interest expense | 220.00M | 197.00M | 195.00M | 226.00M | 238.00M |
| Tax provision | 887.00M | 974.00M | 875.00M | 403.00M | 997.00M |
| Interest income | 220.00M | 197.00M | 195.00M | 226.00M | 238.00M |
| Net interest income | -220.00M | -197.00M | -203.00M | -226.00M | -238.00M |
| Income tax expense | 887.00M | 974.00M | 603.00M | 451.00M | 997.00M |
| Total revenue | 17438.00M | 19128.00M | 18841.00M | 19140.00M | 22106.00M |
| Total operating expenses | 2147.00M | 398.00M | 13579.00M | -14045.00M | -16784.00M |
| Cost of revenue | 10650.00M | 12313.00M | - | 275.00M | - |
| Total other income expense net | -108.00M | 6190.00M | -10274.00M | -226.00M | -238.00M |
| Net income from continuing ops | 3646.00M | 5443.00M | 4370.00M | 4201.00M | 4325.00M |
| Net income applicable to common shares | 3646.00M | 5443.00M | 4659.00M | 4201.00M | 4325.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 116470.00M | 117566.00M | 126724.00M | 131738.00M | 157542.00M |
| Intangible assets | 9034.00M | 8758.00M | 9132.00M | - | - |
| Other current assets | 718.00M | -72277.00M | -78444.00M | 41518.00M | 43721.00M |
| Total liab | 86980.00M | 91468.00M | 104739.00M | 111598.00M | 124289.00M |
| Total stockholder equity | 29490.00M | 26098.00M | 21985.00M | 20140.00M | 33253.00M |
| Other current liab | -1368.00M | -573.00M | -577.00M | 4236.00M | 4339.00M |
| Common stock | 136.00M | 136.00M | 136.00M | 135.00M | 135.00M |
| Capital stock | 136.00M | 136.00M | 136.00M | 135.00M | 135.00M |
| Retained earnings | 54682.00M | 52277.00M | 47993.00M | 44367.00M | 41381.00M |
| Other liab | - | - | - | 91714.00M | 116333.00M |
| Good will | 260.00M | 263.00M | 265.00M | 265.00M | 268.00M |
| Other assets | - | 117566.00M | 126724.00M | -45011.00M | 157542.00M |
| Cash | 6245.00M | 6229.00M | 4306.00M | 3943.00M | 5051.00M |
| Cash and equivalents | 6245.00M | 6229.00M | 4306.00M | 3943.00M | 5051.00M |
| Total current liabilities | - | 573.00M | 2210.00M | 1296.00M | 7956.00M |
| Net debt | 2164.00M | 1269.00M | 3058.00M | 3499.00M | 2905.00M |
| Short term debt | 0.00M | 124.00M | 52.00M | 7442.00M | 7956.00M |
| Short long term debt total | 8409.00M | 7498.00M | 7364.00M | 7442.00M | 7956.00M |
| Other stockholder equity | -26780.00M | -23337.00M | -20624.00M | -17933.00M | -15656.00M |
| Property plant equipment | 351.00M | 387.00M | 445.00M | 530.00M | 538.00M |
| Total current assets | 7798.00M | 4021.00M | 29071.00M | 80331.00M | 143671.00M |
| Long term investments | 81128.00M | 82031.00M | 92197.00M | 80556.00M | 115061.00M |
| Net tangible assets | - | - | - | 22365.00M | 33253.00M |
| Short term investments | 64153.00M | 65269.00M | 73290.00M | 75741.00M | 98696.00M |
| Net receivables | 835.00M | 779.00M | 848.00M | 647.00M | 693.00M |
| Long term debt | 8409.00M | 7402.00M | 7240.00M | 7442.00M | 7839.00M |
| Inventory | - | - | -78444.00M | - | - |
| Accounts payable | - | - | - | 1296.00M | 4339.00M |
| Accumulated other comprehensive income | 1452.00M | -2978.00M | -5520.00M | -6429.00M | 7393.00M |
| Common stock total equity | - | - | - | 135.00M | 135.00M |
| Retained earnings total equity | - | - | - | 44568.00M | 41381.00M |
| Treasury stock | - | - | - | -20574.00M | -18185.00M |
| Non currrent assets other | 1772.00M | -91439.00M | -92642.00M | -96418.00M | -142977.91M |
| Non current assets total | 108672.00M | 110558.00M | 123553.00M | 96418.00M | 538.00M |
| Capital lease obligations | 79.00M | 96.00M | 124.00M | 147.00M | 117.00M |
| Long term debt total | 8409.00M | 7326.00M | 7243.00M | 7442.00M | 7851.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -985.00M | 2781.00M | 1536.00M | -1534.00M | -1125.00M |
| Change to liabilities | - | - | - | 103.00M | 1094.00M |
| Total cashflows from investing activities | 1561.00M | 2781.00M | 817.00M | -1540.00M | -2378.00M |
| Net borrowings | 955.00M | 629.00M | 204.00M | -222.00M | 417.00M |
| Total cash from financing activities | -4069.00M | -3486.00M | -3723.00M | -3551.00M | -2739.00M |
| Change to operating activities | - | - | - | 661.00M | 976.00M |
| Net income | 3646.00M | 5443.00M | 4659.00M | 4201.00M | 4325.00M |
| Change in cash | 16.00M | 1923.00M | 363.00M | -1108.00M | -90.00M |
| Begin period cash flow | 6229.00M | 4306.00M | 3943.00M | 5051.00M | 5141.00M |
| End period cash flow | 6245.00M | 6229.00M | 4306.00M | 3943.00M | 5051.00M |
| Total cash from operating activities | 2555.00M | 2707.00M | 3190.00M | 3879.00M | 5051.00M |
| Issuance of capital stock | 8.00M | 14.00M | 11.00M | 17.00M | 26.00M |
| Depreciation | - | - | 39.00M | 1152.00M | 1170.00M |
| Other cashflows from investing activities | 1863.00M | 1900.00M | 95.00M | -6.00M | -1253.00M |
| Dividends paid | 1198.00M | 1087.00M | 966.00M | -979.00M | -855.00M |
| Change to account receivables | - | 51.00M | -133.00M | 2.00M | 72.00M |
| Sale purchase of stock | -3530.00M | -2800.00M | -2801.00M | -2401.00M | -2301.00M |
| Other cashflows from financing activities | -304.00M | -242.00M | -177.00M | 1228.00M | 1091.00M |
| Change to netincome | - | - | - | -525.00M | -547.00M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change receivables | - | - | - | 2.00M | 72.00M |
| Cash flows other operating | - | - | - | -1054.00M | -1063.00M |
| Exchange rate changes | - | - | - | - | -24.00M |
| Cash and cash equivalents changes | - | - | - | -1212.00M | -90.00M |
| Change in working capital | -1432.00M | -644.00M | -1652.00M | 105.00M | 1166.00M |
| Stock based compensation | - | - | 79.00M | 6.00M | - |
| Other non cash items | 341.00M | -2092.00M | 183.00M | -427.00M | -440.00M |
| Free cash flow | 2555.00M | 2707.00M | 3190.00M | 3879.00M | 5051.00M |
Sector: Financial Services Industry: Insurance - Life
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
|---|---|---|---|---|---|---|---|
| AFL Aflac Incorporated |
-2.18 1.73% |
124.06 | 17.00 | 14.53 | 3.54 | 2.00 | 3.76 |
| PIAIF Ping An Insurance |
- -% |
5.96 | 5.78 | 5.15 | 0.13 | 0.85 | 1.31 |
| CILJF China Life Insurance Co Ltd |
-0.16 4.62% |
3.30 | 2.96 | 5.06 | 0.23 | 1.11 | 1.10 |
| AAGIY AIA Group Ltd ADR |
0.28 0.70% |
40.39 | 12.84 | 11.34 | 3.88 | 2.47 | 2.22 |
| AAIGF AIA Group Ltd |
- -% |
10.08 | 12.45 | 10.93 | 3.86 | 2.38 | 2.21 |
Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. It operates in two segments, Aflac Japan and Aflac U.S. The Aflac Japan segment offers cancer, medical, nursing care, whole life, and GIFT insurance products, as well as WAYS and child endowment, and Tsumitasu insurance products in Japan. Its Aflac U.S. segment provides accident, disability, cancer, critical illness, hospital indemnity, dental, vision, and life insurance products in the United States. The company also provides hearing, final expense, pet, Medicare supplement, supplemental dental and vision, short-term disability, and absence management insurance products, as well as cafeteria plans. It sells its products to individuals, families, and business owners through individual, independent corporate, and affiliated corporate agencies; banks; independent associates/career agents; and brokers. Aflac Incorporated was founded in 1955 and is headquartered in Columbus, Georgia.
| Name | Title | Year Born |
|---|---|---|
| Mr. Daniel Paul Amos | Chairman & CEO | 1952 |
| Mr. Frederick John Crawford | Pres & COO | 1964 |
| Mr. Max Kristian Broden | Exec. VP & CFO | 1979 |
| Mr. Eric Mark Kirsch CFA | Exec. VP, Global Chief Investment Officer & Pres of Aflac Asset Management LLC | 1961 |
| Ms. Audrey Boone Tillman Esq. | Exec. VP & Gen. Counsel | 1965 |
| Ms. June Posey Howard CPA, CFA, CGMA | Sr. VP of Financial Services & Chief Accounting Officer | 1967 |
| Mr. J. Peter Kelso | Sr. VP and Chief Information & Technology Officer | NA |
| Mr. Koichiro Yoshizumi | EVP of Sales & Mrkt. and Director of Sales, Mrkt., Alliance Strategy - Aflac Life Insurance Japan | 1962 |
| Ms. Teresa Lynne White | Pres of Aflac US | 1967 |
| Mr. James Todd Daniels | Exec. VP, Director & CFO of Aflac Life Insurance Japan | 1971 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.